Table 1.

Description of Included Trials

Trial	No. of Patients Randomly Assigned	Inclusion Period	Median Follow-Up (years)	Histology	RT Total Dose (Gy)	No. of Fractions	Duration (weeks)	BED St/EXP	CT Dose	Patient Characteristic
ECOG 358824	417	1989-1992	13.0	SCLC	Standard: 45	25	5	39.5	Cisplatin 60 mg/m2 day 1	PS 0-2
					Experimental: 45	30	3 BID	43.9	Etoposide 120 mg/m2 days 1-3
									4 cycles (3 weeks)
NCCTG 89205225	268	1990-1996	9.3	SCLC	Standard: 50.4	28	5.5	43.8	Cisplatin 30 mg/m2 days 1-3	PS 0-2
					Experimental: 48	32	5.5 SC* BID	39.5	Etoposide 130 mg/m2 days 1-3
									6 cycles† (4 weeks)
RTOG 8808-ECOG 458826	326	1989-1992	6.8	NSCLC	Standard: 60 Gy	30	6	55.5	None	KPS ≥ 70
					Experimental: 69.6	58	6 BID	61.9		Stage II-III
PMCI 88C09127	101	1989-1995	Not reached	NSCLC	Standard: 60	30	6	55.5	None	PS 0-1
					Experimental: 60	30	3 BID	64.2		Stage I-III
PMCI 88C091 CT27	107	1989-1995	Not reached	NSCLC	Standard: 60	30	6	55.5	Carboplatin 70 mg/m2 days 1-5	PS 0-1
					Experimental: 60	30	3 BID	64.2	+ Carboplatin 70 mg/m2 days 29-33 in standard arm	Stage I-III
CHART28	563‡	1990-1995	6.9	NSCLC	Standard: 60	30	6	55.5	None	PS 0-1
					Experimental: 54	36	1.5 TID	57.2		Stage I-III
NCCTG 90245129	74	1992-1993	8.1	NSCLC	Standard: 60	30	6	55.5	None	PS 0-2
					Experimental: 60	40	6 SC§ BID	52.5		Stage III
NCCTG 94245230	246	1994-1999	7.3	NSCLC	Standard: 60	30	6	55.5	Cisplatin 30 mg/m2 days 1-3, 28-30	PS 0-1
					Experimental: 60	40	6 SC§ BID	52.5	Etoposide 100 mg/m2 days 1-3, 28-30	Stage III
CHARTWEL31	300	1997-2005	4.9	NSCLC	Standard: 66	33	6.5	60.6	None	PS 0-1
					Experimental: 60	40	2.5 TID	61.6		Stage I-III
CHARTWEL CT31	106	1997-2005	3.5	NSCLC	Standard: 66	33	6.5	60.6	Induction CT—dependent on institution's choice	PS 0-1
					Experimental: 60	40	2.5 TID	61.6		Stage I-III
ECOG 259732	119	1998-2001	6.7	NSCLC	Standard: 64	32	6.5	58.7	Carboplatin AUC 6 day 1	PS 0-1
					Experimental: 57.6	36	2.5 TID	60.2	Paclitaxel 225 mg/m2 day 1	Stage III
									2 cycles‖ (3 weeks)
Gliwice 200133	58	2001-2006	5.3	NSCLC	Standard: 72	40	8	62.7	None	PS 0-1
					Experimental: 72	40	5.5	68.5		Stage II-III

Abbreviations: BED, biologic effective dose; BID, RT given twice a day; CT, chemotherapy; if not specified, the chemotherapy is concomitant to the radiotherapy; CHART, Continuous Hyperfractionated Accelerated Radiation Therapy; CHARTWEL, CHART Week-End Less; ECOG, Eastern Cooperative Oncology Group; Exp, experimental; (K) PS, (Karnofsky) performance status; NCCTG, North Central Cancer Treatment Group; NSCLC, non–small-cell lung cancer; PCMI, Peter MacCallum Institute; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SC, split course; SCLC, small-cell lung cancer; St, standard; TID, RT given three times a day.

^*Two series of 8 days with a break of 2.5 weeks.

^†Three cycles induction, two cycles concomitant, and one after RT; etoposide dose was reduced to 100 mg/m² for cycles 4 to 6.

^‡Patients were randomly allocated in a 3:2 ratio to CHART or conventional radiotherapy.

^§Two series of 2 weeks with a break of 2 weeks.

^‖Induction chemotherapy.